Production (Stage)
Conduit Pharmaceuticals Inc.
CDT
$2.33
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -41.95% | 100.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.18% | -11.61% | |||
| Operating Income | 16.18% | 11.61% | |||
| Income Before Tax | -113.88% | 62.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -113.88% | 62.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -113.88% | 62.76% | |||
| EBIT | 16.18% | 11.61% | |||
| EBITDA | 11.82% | 19.93% | |||
| EPS Basic | 38.40% | 71.00% | |||
| Normalized Basic EPS | 50.50% | 53.71% | |||
| EPS Diluted | 38.40% | 71.00% | |||
| Normalized Diluted EPS | 50.50% | 53.71% | |||
| Average Basic Shares Outstanding | 247.23% | 28.40% | |||
| Average Diluted Shares Outstanding | 247.23% | 28.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||